Flex Pharma, which is developing dietary supplements for the treatment of muscle cramps and spasms, announced terms for its IPO on Tuesday. The Boston, MA-based company plans to raise $60 million by offering 4.6 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Flex Pharma would command a fully diluted market value of $231 million.
Flex Pharma, which was founded in 2014, plans to list on the NASDAQ under the symbol FLKS. Jefferies and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of January 26, 2015.
